In a multinational, placebo-controlled trial, rosuvastatin proved to be well-tolerated in patients with dyslipidemia. The 33-trial program included >16,800 patients who represented >25,000 patient-years of continuous exposure to rosuvastatin. The patients received 5 to 40 mg of the drug or placebo. Adverse events occurred in 52.1% of the rosuvastatin group and 51.8% of the placebo group, giving it an adverse-event profile similar to that of atorvastatin 10 to 80 mg, simvastatin 10 to 80 mg, and pravastatin 10 to 40 mg.
5 Studies That Shaped HIV Treatment That Every Pharmacist Should Know
Over the years, a number of landmark clinical studies in the field of virology have been published, shaping how we treat many infectious diseases today.
News from the year's biggest meetings
Clinical features with downloadable PDFs